INTRODUCTION: The effect of a single dose of methylphenidate (MPH) on cognitive measures and decision-making processes was assessed in a sample of adults with ADHD and in a control sample. METHODS:Thirty-two adults satisfying DSM-IV criteria for ADHD and 26 healthy controls performedseveral cognitive tasks. Half of the participants received MPH prior to performing the tasks, and the other half received placebo in a randomized, double-blind manner. RESULTS: The average digit-span test score was higher in the groups receiving MPH compared to the groups receiving placebo, while diagnosis did not have an effect upon scores. In decision-making tasks, however, MPH did not have an effect upon performance, whereas in one of the tasks the average proportion of risky choices was higher in ADHD adults compared to controls. CONCLUSION: Our data therefore demonstrates that (a) MPH is capable of enhancing specific aspects of cognitive performance and (b) this enhancement is not specific to ADHD.
RCT Entities:
INTRODUCTION: The effect of a single dose of methylphenidate (MPH) on cognitive measures and decision-making processes was assessed in a sample of adults with ADHD and in a control sample. METHODS: Thirty-two adults satisfying DSM-IV criteria for ADHD and 26 healthy controls performed several cognitive tasks. Half of the participants received MPH prior to performing the tasks, and the other half received placebo in a randomized, double-blind manner. RESULTS: The average digit-span test score was higher in the groups receiving MPH compared to the groups receiving placebo, while diagnosis did not have an effect upon scores. In decision-making tasks, however, MPH did not have an effect upon performance, whereas in one of the tasks the average proportion of risky choices was higher in ADHD adults compared to controls. CONCLUSION: Our data therefore demonstrates that (a) MPH is capable of enhancing specific aspects of cognitive performance and (b) this enhancement is not specific to ADHD.
Authors: Nicholas J Cooper; Hannah Keage; Daniel Hermens; Leanne M Williams; David Debrota; C Richard Clark; Evian Gordon Journal: J Integr Neurosci Date: 2005-03 Impact factor: 2.117
Authors: C J Vaidya; G Austin; G Kirkorian; H W Ridlehuber; J E Desmond; G H Glover; J D Gabrieli Journal: Proc Natl Acad Sci U S A Date: 1998-11-24 Impact factor: 11.205
Authors: J C Kurscheidt; P Peiler; A Behnken; S Abel; A Pedersen; T Suslow; J Deckert Journal: J Neural Transm (Vienna) Date: 2008-02-12 Impact factor: 3.575
Authors: Patrick C Dolder; Petra Strajhar; Patrick Vizeli; Alex Odermatt; Matthias E Liechti Journal: Psychopharmacology (Berl) Date: 2018-02-09 Impact factor: 4.530
Authors: Lisa S Kahalley; Heather M Conklin; Vida L Tyc; Stephanie J Wilson; Pamela S Hinds; Shengjie Wu; Xiaoping Xiong; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2011-02-18 Impact factor: 3.167
Authors: Marieke E van der Schaaf; Sean J Fallon; Niels Ter Huurne; Jan Buitelaar; Roshan Cools Journal: Neuropsychopharmacology Date: 2013-04-23 Impact factor: 7.853
Authors: Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir Journal: Exp Clin Psychopharmacol Date: 2016-08 Impact factor: 3.157